TRIKAFTA/KAFTRIO — Product revenues, net
Vertex Pharmaceuticals TRIKAFTA/KAFTRIO — Product revenues, net decreased by 3.1% to $2.57B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.5%, from $2.72B to $2.57B. Over 4 years (FY 2021 to FY 2025), TRIKAFTA/KAFTRIO — Product revenues, net shows an upward trend with a 16.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration, patient adherence, or expanded access to the therapy, while a decrease may signal increased competition, patent expirations, or market saturation.
Detailed definition
This metric represents the net sales generated from the company's primary cystic fibrosis therapeutic franchise after ac...
Peer comparison
Comparable to flagship product revenue lines in other biotechnology or pharmaceutical companies that rely on a dominant therapeutic franchise for the majority of their cash flow.
vrtx_segment_trikafta_kaftrio_product_revenues_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.26B | $1.56B | $1.69B | $1.76B | $1.89B | $2.01B | $2.02B | $2.10B | $2.24B | $2.27B | $2.33B | $2.48B | $2.45B | $2.59B | $2.72B | $2.54B | $2.55B | $2.65B | $2.57B |
| QoQ Change | — | +23.9% | +8.8% | +4.1% | +7.5% | +6.2% | +0.5% | +3.7% | +6.9% | +1.5% | +2.6% | +6.4% | -1.4% | +5.5% | +5.3% | -6.8% | +0.6% | +4.0% | -3.1% |
| YoY Change | — | — | — | — | +50.8% | +29.2% | +19.4% | +19.0% | +18.3% | +13.1% | +15.4% | +18.5% | +9.3% | +13.7% | +16.6% | +2.1% | +4.2% | +2.7% | -5.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's trikafta/kaftrio — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported trikafta/kaftrio — product revenues, net of $2.57B in Q4 2025.
- How has Vertex Pharmaceuticals's trikafta/kaftrio — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's trikafta/kaftrio — product revenues, net decreased by 5.5% year-over-year, from $2.72B to $2.57B.
- What is the long-term trend for Vertex Pharmaceuticals's trikafta/kaftrio — product revenues, net?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's trikafta/kaftrio — product revenues, net has grown at a 16.0% compound annual growth rate (CAGR), from $5.70B to $10.31B.
- What does trikafta/kaftrio — product revenues, net mean?
- The total net revenue earned from the sale of the company's primary cystic fibrosis medication franchise.